Tillman Gerngross (Photo by Craig F. Walker/The Boston Globe via Getty Images)
May 10, 2022 07:11 AM EDT
People

Till­man Gern­gross pass­es the Adimab ba­ton af­ter 15 years, mov­ing from CEO to ex­ec­u­tive chair­man role

Amber Tong

A new era is un­fold­ing at Adimab.

Fif­teen years af­ter he co-found­ed the an­ti­body dis­cov­ery shop, Till­man Gern­gross is step­ping down as CEO — hand­ing the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

A service from the Financial Times